Nocion Therapeutics
WALTHAM, MA · Biotechnology, Healthcare · 9 employees
Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safe
Funding history
- Venture - Series Unknown — $23.0M — Mar 2026
- Series B — $23.0M — Jan 2026
- Venture - Series Unknown — $31.1M — Mar 2024
- Series B — $62.0M — Mar 2024
- Venture - Series Unknown — $7.0M — Aug 2022
Recent signals
- May 27, 2026: Nocion Therapeutics Appoints Vineet Agarwal as Chief Business Officer
- Mar 13, 2026: Raised $23.0M in Venture - Series Unknown
- Jan 07, 2026: Raised $23.0M in Series B
- Apr 28, 2025: Nocion Therapeutics Appoints Matthew Frankel as Chief Medical Officer
- Mar 13, 2024: Raised $31.1M in Venture - Series Unknown
- Mar 04, 2024: Raised $62.0M in Series B
- Aug 24, 2022: Raised $7.0M in Venture - Series Unknown
- Aug 31, 2021: Raised $7.0M in Venture - Series Unknown
See plans & pricing → Track Nocion Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.